The potential imbalances in endothelin signaling imparted by anti-ETAR and anti-ETBR autoantibodies may lead to increased end-organ inflammation, subsequent organ damage, and cardiovascular disease development in SLE. Here, EDNRB is linked to cardiovascular disorder.